Symbiotec Pharmalab
Demand
Strong
subscribed 5.62x overall
Grey market
+18.7%
implied listing pop
History says
+17.6%
median at this premium · middle half +11% to +27% · n=42
Latest GMP
₹185
grey-market premium
Implied pop
+18.7%
GMP over issue price
History says
+17.6%
median actual listing at this GMP (n=42)
Range of outcomes
middle half of 42 listings at this GMP
GMP trend
14 street quotes since 08/31
Final Subscription
Subscribed 5.62xoverall · last updated 2026-08-27 00:45 UTC
| Category | Shares reserved | 25-08 | 26-08 | 27-08 | |||
|---|---|---|---|---|---|---|---|
| Shares bid | Times | Shares bid | Times | Shares bid | Times | ||
| QIB | 8,876,517 | 5,059,615 | 0.57× | 5,503,441 | 0.62× | 5,503,441 | 0.62× |
| ∟QIB (Ex Anchor) | 3,550,608 | – | – | – | – | – | – |
| NII | 2,662,955 | 6,577,499 | 2.47× | 28,786,544 | 10.81× | 34,245,601 | 12.86× |
| ∟bNII (> ₹10L) | 1,775,303 | – | – | – | – | – | – |
| ∟sNII (< ₹10L) | 887,652 | – | – | – | – | – | – |
| Retail | 6,213,562 | 12,240,717 | 1.97× | 29,576,555 | 4.76× | 33,428,964 | 5.38× |
| Employee | 33,408 | 93,208 | 2.79× | 187,085 | 5.60× | 208,800 | 6.25× |
| Total | 17,786,442 | 29,881,223 | 1.68× | 86,619,973 | 4.87× | 99,959,804 | 5.62× |
Allotment odds (1 lot lottery once oversubscribed) — Retail: ≈ 1 in 6 applicants
Allotment Probability
Retail · subscribed 5.38x
19%
HNI / NII · subscribed 12.86x
8%
Chance of winning at least one lot per application, from the shares reserved for the category vs current demand. QIB allots pro-rata, not by lottery. Demand can spike on the final day.
📋Issue Details
| Offer Type | Bookbuilding IPO |
| Sale Type | Fresh capital cum OFS |
| Listing At | BSE, NSE |
| Face Value | ₹ 2 per share |
| Price Band | ₹938 to ₹988 |
| Lot Size | 15 shares |
| Total Issue Size | 1,77,86,442 shares (agg. up to ₹ 1,757 Cr) |
| Fresh Issue | 15,21,261 shares (agg. up to ₹ 150 Cr) |
| Offer for Sale | 1,62,65,181 shares of ₹ 2 (agg. up to ₹ 1,607 Cr) |
🗓️IPO Schedule
Open
Mon, Aug 24, 2026
Close
Thu, Aug 27, 2026
Allotment
Fri, Aug 28, 2026
Refunds
Mon, Aug 31, 2026
Demat credit
Mon, Aug 31, 2026
Listing
Tue, Sep 1, 2026
🏛️Pre & Post Issue Capital
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 34.47% | |
| Public | 65.53% | |
| Total | 100% |
💰Valuation & Market Cap
| EPS(₹) (pre → post) | 17.82 → 17.39 |
| P/E (x) (pre → post) | 55.44 → 56.81 |
| Market Cap at Offer Price | ₹6,244.43 Cr |
📊Company Financials ₹ crore
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
🎯Key Performance Indicators
| ROE | 11.19% |
| ROCE | 11.56% |
| RoNW | 9.48% |
| PAT Margin | 12.60% |
| EBITDA Margin | 26.59% |
| NAV | 184.69 |
| Price to Book Value | 5.35 |
🤝Recently Listed PeersPharmaceuticals
| Company | Issue price | P/E | Listing-day close |
|---|---|---|---|
| Hexagon Nutrition Ltd. | ₹45 | 22.69 | ₹53.19 |
| Sai Parenteral's Ltd. | ₹392 | 72.19 | ₹405.70 |
| Corona Remedies Ltd. | ₹1062 | 43.47 | ₹1,438.40 |
| Rubicon Research Ltd. | ₹485 | 55.75 | ₹628.20 |
| Amanta Healthcare Ltd. | ₹126 | 34.59 | ₹141.75 |
| Anlon Healthcare Ltd. | ₹91 | 17.67 | ₹91.73 |
| Bio Medica Laboratories Ltd. | ₹139 | 13.03 | ₹115.80 |
| Goldline Pharmaceutical Ltd. | ₹43 | 10.47 | ₹56.77 |
Lot Size — what an application costs
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Issue Reservation
| Category | Shares | % of issue | Max allottees |
|---|---|---|---|
| QIB | 88,76,517 | 50.00% | 49.91% |
| − Anchor Investor | 53,25,909 | 29.94% | |
| − QIB (Ex. Anchor) | 35,50,608 | 19.96% | |
| NII (HNI) | 26,62,955 | 15.00% | 14.97% |
| − bNII > ₹10L | 17,75,303 | 9.98% | |
| − sNII < ₹10L | 8,87,652 | 4.99% | |
| Retail | 62,13,562 | 35.00% | 34.93% |
| Employee | 33,408 | 0.19% | |
| Total | 1,77,86,442 | 100.00% | 100.00% |
GMP trend
| Date | GMP ₹ | Implied |
|---|---|---|
| 2026-09-02 | 185 | +18.7% |
| 2026-09-02 | 185 | +18.7% |
| 2026-09-01 | 185 | +18.7% |
| 2026-09-01 | 185 | +18.7% |
| 2026-09-01 | 185 | +18.7% |
| 2026-09-01 | 185 | +18.7% |
| 2026-09-01 | 185 | +18.7% |
| 2026-09-01 | 205 | +20.8% |
| 2026-08-31 | 205 | +20.8% |
| 2026-08-31 | 205 | +20.8% |
| 2026-08-31 | 205 | +20.8% |
| 2026-08-31 | 205 | +20.8% |
| 2026-08-31 | 260 | +26.3% |
| 2026-08-31 | 260 | +26.3% |
🏢About Symbiotec Pharmalab
Symbiotec Pharmalab IPO is a book build issue of ₹1,757.00 crores. The issue is a combination of fresh issue of 15.21 lakh shares aggregating to ₹150.00 crores and offer for sale of 1.63 crore shares aggregating to ₹1,607.00 crores.
Symbiotec Pharmalab IPO bidding opened for subscription on Aug 24, 2026 and will close on Aug 27, 2026. The allotment for the Symbiotec Pharmalab IPO is expected to be finalized on Aug 28, 2026. Symbiotec Pharmalab IPO will list on NSE and BSE with a tentative listing date fixed as Sep 1, 2026.
Symbiotec Pharmalab IPO is set issue price band at ₹938 to ₹988 per share. The lot size for an application is 15 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,820 (15 shares) (based on upper price).
The issue includes a reservation of up to 33,408 shares for employees offered at a discount of ₹90.00 to the issue price.
🎯Objects of the Issue
| Object | ₹ Cr |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstandin | 112.50 |
| General corporate purposes | – |
💼Lead Managers
- • JM Financial Ltd.
- • Avendus Capital Pvt.Ltd.
- • Motilal Oswal Investment Advisors Ltd.
- • Nomura Financial Advisory & Securities (India) Pvt.Ltd.
🗳️Registrar
- • MUFG Intime India Pvt.Ltd.
- allotment status is checked on the registrar's portal
🏢Registered Office
📍 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331
📞 +91 731 667 6405
✉️ secretarial@symbiotec.com
Grey-market numbers are unofficial street quotes, aggregated across sources. Not investment advice.